Effects of pomegranate juice consumption on diabetes complications

Effects of Pomegranate juice consumption on serum vascular and systematic inflammation factors, advanced glycation end products, NF-kB and Sirtuin1 activity in mononuclear cells in type2 diabetic patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201206144010N8

Enrollment

Registered

2012-07-12

Start date

2012-06-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes type 2. Diabetes mellitus

Interventions

Intervention 1: 240 ml/day of PJ (without added sugar or additives) providing 126 Kcal, fat 0g, protein 1.4 g, and 23.5 g sugar for 3 months. Intervention 2: 240 ml/day of a control beverage of simila

Placebo

240 ml/day of PJ (without added sugar or additives) providing 126 Kcal, fat 0g, protein 1.4 g, and 23.5 g sugar for 3 months

240 ml/day of a control beverage of similar color and energy and glucose content for 3 months

Eligibility

Sex/Gender

All

Age

40 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Diabetes type 2; 40-65 years old; BMI=18.5-30; Control of diabetes only by oral agents. Exclusion criteria: Liver and kidney diseases; Inflammatory diseases; Consumption of multivitamin and/or mineral supplements in the past 3 months; Consumption of corticosteroid, anti-inflammatory, non-steroid medications; Changing in type and dosage of used medications during the study; Changing in physical activity type and levels, during the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
TNF-a. Timepoint: at baseline and after 3 months at the end of the study. Method of measurement: ELISA , ng/L.;Hs-CRP. Timepoint: at baseline and after 3 months at the end of the study. Method of measurement: ELISA , ng/mL.;IL-6. Timepoint: at baseline and after 3 months at the end of the study. Method of measurement: ELISA , ng/L.;ICAM-1. Timepoint: at baseline and after 3 months at the end of the study. Method of measurement: ELISA , ng/mL.;VCAM-1. Timepoint: at baseline and after 3 months at the end of the study. Method of measurement: ELISA , ng/mL.;E-selectin. Timepoint: at baseline and after 3 months at the end of the study. Method of measurement: ELISA , ng/mL.;Pentosidine. Timepoint: at baseline and after 3 months at the end of the study. Method of measurement: ELISA , ng/mL.;Carboxy Methyl Lysin. Timepoint: at baseline and after 3 months at the end of the study. Method of measurement: ELISA , ng/mL.;HbA1C. Timepoint: at baseline and after 3 months at the end of the study. Method of measurement: Cromatography, Percent.;Glucose. Timepoint: at baseline and after 3 months at the end of the study. Method of measurement: calorimetry, mg/dl.;Insulin. Timepoint: at baseline and after 3 months at the end of the study. Method of measurement: ELISA, mU/L.;HOMA-IR. Timepoint: at baseline and after 3 months at the end of the study. Method of measurement: Calculate,(glucose×Insulin)/22.5.;NF-kB activity. Timepoint: at baseline and after 3 months at the end of the study. Method of measurement: ELISA.;Srtuin1 activity. Timepoint: at baseline and after 3 months at the end of the study. Method of measurement: ELISA , ng/mL.	—

Measure

Time frame

TNF-a. Timepoint: at baseline and after 3 months at the end of the study. Method of measurement: ELISA , ng/L.;Hs-CRP. Timepoint: at baseline and after 3 months at the end of the study. Method of measurement: ELISA , ng/mL.;IL-6. Timepoint: at baseline and after 3 months at the end of the study. Method of measurement: ELISA , ng/L.;ICAM-1. Timepoint: at baseline and after 3 months at the end of the study. Method of measurement: ELISA , ng/mL.;VCAM-1. Timepoint: at baseline and after 3 months at the end of the study. Method of measurement: ELISA , ng/mL.;E-selectin. Timepoint: at baseline and after 3 months at the end of the study. Method of measurement: ELISA , ng/mL.;Pentosidine. Timepoint: at baseline and after 3 months at the end of the study. Method of measurement: ELISA , ng/mL.;Carboxy Methyl Lysin. Timepoint: at baseline and after 3 months at the end of the study. Method of measurement: ELISA , ng/mL.;HbA1C. Timepoint: at baseline and after 3 months at the end of the study. Method of measurement: Cromatography, Percent.;Glucose. Timepoint: at baseline and after 3 months at the end of the study. Method of measurement: calorimetry, mg/dl.;Insulin. Timepoint: at baseline and after 3 months at the end of the study. Method of measurement: ELISA, mU/L.;HOMA-IR. Timepoint: at baseline and after 3 months at the end of the study. Method of measurement: Calculate,(glucose×Insulin)/22.5.;NF-kB activity. Timepoint: at baseline and after 3 months at the end of the study. Method of measurement: ELISA.;Srtuin1 activity. Timepoint: at baseline and after 3 months at the end of the study. Method of measurement: ELISA , ng/mL.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGolbon Sohrab

Faculty of Nutrition Sciences and Food technology, Shahid Beheshti University of Medical Sciences

golbonsohrab@yahoo.com+98 21 4445 0097

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026